TGTX — TG THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1001316 ·
Last close
$62.71
Market Cap
$9.48B
52W High
$68.03
52W Low
$26.76
ADV30
1,895,175
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 240,335,000 | 199,141,000 | 21,674,000 | 7,781,000 | 1,639,629,000 | 482,575,000 | 1,035,546,000 |
| Mar 2026 | 204,918,000 | 171,408,000 | 34,795,000 | 19,777,000 | 1,528,837,000 | 442,209,000 | 945,706,000 |
| Dec 2025 | 192,574,000 | 154,432,000 | 50,494,000 | 23,037,000 | 1,063,253,000 | 79,148,000 | 415,233,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$86,256,000
Investing CF
$-23,142,000
Financing CF
$292,227,000
CapEx
$-693,000
Dividends Paid
$0
Buybacks
$-199,990,000
EPS Diluted TTM
$0.66
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-998,994,000
Inventory
$194,319,000
Receivables
$416,821,000
ST Investments
$75,295,000
EBIT TTM
$196,142,000
Pretax Income TTM
$149,552,000
Interest Exp TTM
$46,590,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$897,763,008
EBITDA
$193,040,992
Free Cash Flow
$85,523,000
Enterprise Value
$9,287,474,176
Total Cash
$504,671,008
Total Debt
$754,372,992
Shares Out
151,147,827
Trailing EPS
$0.67
Book Value
$4.08
ROE
18.0%
ROA
9.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 616,287,000 | 123,324,000 | 447,179,000 | 1,063,253,000 | 415,233,000 | 648,020,000 | -24,772,000 |
| Dec 2024 | 329,004,000 | 41,929,000 | 23,383,000 | 577,690,000 | 355,326,000 | 222,364,000 | -40,517,000 |
| Dec 2023 | 233,662,000 | 20,633,000 | 12,672,000 | 329,587,000 | 169,085,000 | 160,502,000 | -31,413,000 |
| Dec 2022 | 2,785,000 | -218,316,000 | -223,812,000 | 193,572,000 | 134,985,000 | 58,587,000 | -176,170,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$799,536,000
NetIncome TTM
$441,490,000
OpCashFlow TTM
—
Assets (Latest)
$1,639,629,000
Forward EPS
$2.55
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $60.00 · spot: $66.12 · call volume: 1,809 · put volume: 121
Expected Move to 2026-12-18:
±$7.58
(11.46%) —
implied range
$58.54 –
$73.70
· ATM straddle on $65.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $9.80B | $421.99 | — |
| SYRE | Spyre Therapeutics, Inc. | $8.91B | $93.81 | — |
| SMMT | Summit Therapeutics Inc. | $8.53B | $10.67 | — |
| PRAX | Praxis Precision Medicines, Inc. | $8.53B | $305.06 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $8.08B | $116.61 | — |
News headlines (Yahoo Finance, 1h cache)
TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™
2026-11-18 12:30 · Yahoo
TG Therapeutics: 3 Key Takeaways for Long-Term Investors
2026-11-15 02:32 · Yahoo
The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
2026-11-11 06:36 · Yahoo
TG Therapeutics (TGTX) Lifts Revenue Guidance As Investors Ask If The Stock Is Pricey
2026-11-11 03:12 · Yahoo
How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis
2026-11-10 22:12 · Yahoo
Is Earnings Beat Altering The Investment Case For TG Therapeutics (TGTX)?
2026-11-10 22:11 · Yahoo
TG Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-10 03:11 · Yahoo
TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript
2026-11-10 02:03 · Yahoo
TG Therapeutics Inc (TGTX) (Q3 2026) Earnings Call Highlights: Revenue Jumps 61% as Guidance ...
2026-11-09 21:07 · Yahoo
What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call
2026-11-09 18:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.